In the present study, a series of N-{4- [(4-amino-5-sulfanyl-4H-1,2,4-triazol-3-yl)methyl]-1,3-thiazol-2-yl}-2-substituted amide derivatives (1a-d) were synthesized in good yields and characterized. The compounds were evaluated for their preliminary in vitro antibacterial activity against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Salmonella typhosa and then were screened for antitubercular activity against Mycobacterium tuberculosis H37 Rv strain by the MABA assay method. The antibacterial data of the tested compounds indicated that compounds 6b, 6c, 8a, 8b and 8c showed better activity against bacteria compared to reference drugs. The in vitro antitubercular activity reports of compounds tested against M. tuberculosis strain H37 Rv showed better activity by 8a, 8b and 8c.
Introduction
Tuberculosis remains the major cause of death over the world and the emergence of multi-drug resistant tuberculosis has made the condition most alarming. Up to 4% of all tuberculosis cases worldwide are resistant to more than one antitubercular drug because of incomplete or partial therapy. 1 Therefore, there is an urgent demand for a new class of antitubercular agent with a different mode of action and it has led medicinal chemists to explore a wide variety of chemical structures. While reports [2] [3] [4] are available stating the emergence of thiazoles and/or triazoles as potent antitubercular agents, appreciation of these findings, coupled with our observation that, today, the trend in antimycobacterial drug design [5] [6] [7] is to join together two or three molecules having different sites or mechanisms of action, initiated our construction of compounds Schiff bases, the condensation products of 8a-d, were synthesized by treating 6a-d with benzaldehyde and confirmed by the absence of the hydrazide NH triplet.
Compounds 6a-d were converted to thiocarbazate salts by treatment with carbon di sulphide and potassium hydroxide, which on treatment with hydrazine hydrate gave 9a-d. The NMR spectra confirmed formation of triazole derivatives from the hydrazides by the presence of the sulfhydryl proton at 12.5 δ. We have also performed a cytotoxicity analysis of the abovesynthesized compounds, using neutral red uptake by using the Vero-C-1008 cell line at various concentrations (6.25 µg/mL to 50 µg/mL), none of them were found toxic. Hence the activities of the above-synthesized compounds were not due to cytotoxicity of the compounds. During the preliminary screening, four compounds 1a-d were tested (Table 2) at 25 µg/mL concentration for their antimycobacterial activity. One of the compounds, viz. 1b exhibited 96% inhibition at this concentration while other compounds exhibited less than 90% inhibition at the same concentration.
Thus, we have considered 1b as a lead molecule and subsequent structural modifications were carried out. As a first step towards lead optimization, the amino group was protected to the corresponding acetamide 2a-d, however, all of these modifications resulted in a substantial decrease in activity. The next structural modification made was a dimeric product of 2a-d but this change also resulted in a substantial loss of biological activity.
Compounds 4b and 4c showed 97% inhibition at 25 µg/mL (Table 2) , which was obtained by S-alkylation with acetonitrile. Thus, looking at the activity, it was decided to modify the structure at the SH group. In order to optimize the sulfhydryl component, four compounds 5a-d were synthesized and investigated, which revealed loss of activity. A further modification of compounds 5a-d produced compounds 6a-d. The results of the antimycobacterial activity are quite interesting because all of these compounds have shown inhibition above 90% at 25 µg/mL (Table 2) .
On the other hand, in secondary screening at 12.5 µg/mL concentration these compounds were found to have decreased antimycobacterial activity. Compounds 6a-d were selected for further studies as they had a protected and free amino group, which opened an area for further modification at this point. Compounds 7a-l were obtained by treatment with acid chlorides, which ultimately showed decreased antimycobacterial activity. Furthermore, compounds 6a-d were investigated after conversion to Schiff bases with benzaldehyde, all of the compounds 8a-d showed more than 95% inhibition at 25 µg/mL concentration and, more interestingly, compounds 8a, 8b and 8c showed more than 94% inhibition at 12.5 µg/mL concentration. Although we have not been able to substantially enhance the activity of these compounds in the present study, the data presented here are encouraging and deserve further investigation.
Antimicrobial activity
The compounds listed in Table 1 were screened for antimicrobial activity against different microorganisms under the following conditions. Method: Well diffusion method, 14 Medium: The nutrient agar medium, Solvent: Chloroform. Concentrations: 50µM and 100 µM. Condition: 24 hours at 24-28 °C, Standard: The antibiotic Gentamycin The nutrient agar medium, 20 mL was poured into the sterile petri dishes. To the solidified plates, wells were made using a sterile cork borer 10 mm in diameter. The 24 hour subcultured bacteria was inoculated in the petri-plates, with a sterile cotton swab dipped in the nutrient broth medium. After inoculating, the compounds were dissolved separately with the chloroform solvent and poured into the wells with varying concentrations ranging from 50 and 100 µM using a micropipette. The plates were left over 24 hours at 24-28 °C. The antibiotic Gentamycin was used as a standard for comparative study. The percentage of inhibition was calculated by the formula % Inhibition = Diameter of the inhibition zone x 100 From these data, it has been found that all the compounds tested showed a broad spectrum of inhibitory properties. From the antibacterial screening it was observed that all the compounds exhibited activity against all the organisms employed. Looking at the structure activity relationship, marked inhibition in bacteria was observed with compounds 6b, 6c, 8a, 8b and 8c, whereas 1d, 3a, 4b, 4c, and 4d have shown moderate activity and others showed the least activity. 
Preparation of N-[3-(4-acetylamino-5-{[2-(acetylcarbonylamino)(1,3-thiazol-4-yl)] methyl}(1,2,4-triazol-3-ylthio))-5-{[2-(acetylcarbonylamino)(1,3-thiazol-4-yl)]methyl} (1,2,4-triazol-4-yl)]acetamide (3b).
The triazole 2b (0.01 mol), diiodomethane (0.01 mol) and 5.6 g (0.01 mol) potassium hydroxide were dissolved in 20 mL of dichloromethane. To the said mixture acidic alumina (20 g) was added. Dichloromethane was evaporated invacuo, and mixture was kept inside the alumina bath and irradiated for 5-6 min at the power level of 300W. The mixture was cooled. The solid thus separated was dissolved in hot ethanol, filtered. After cooling, the filtrate gave white crystals of product 3b. Other compounds in this series were prepared in similar way. Yield 77 %; brown; mp 262-264° C; 1 1,2,4-triazol-3-ylthio))(1,2,4-triazol-3-yl)]-methyl}(1,3-thiazol-2-yl) {(2-(phenylamino)(1,3-thiazol-4-yl)]methyl}-4-acetylamino-1,2,4-triazol-3 1,2,4-triazol-4-yl) )-acetamide (VIb) A solution of 5b (0.01 mol) with 5 mL (0.01 mol) hydrazine hydrate was prepared in 10 mL ethanol. To this acidic alumina was added. Ethanol then was evaporated invacuo, and mixture was kept inside the alumina bath and irradiated for 5-6 min at the power level of 300W. The mixture was cooled and the product was extracted with ether. Ether was distilled off and product thus obtained was crystallized from n-hexane-carbon tetrachloride mixture. Other compounds in this series were prepared in similar way. Yield 82%; brown; mp 250-252° C; 1 
N-(4-{[4-acetylamino-5-[4-(2-chloroacetylamino)-5-{[2-(2-chloroacetylamino)(1,3-thiazol-4-yl)]methyl}(

3-{[4-({5-[5-({2-[(2-carboxyethyl)amino](1,3-thiazol-4-yl)}methyl)-4-(acetylamino) (1,2,4-triazol-3-ylthio)]-4-(acetylamino)-1,2,4-triazol-3-yl}methyl)-1,3-thiazol-2-yl]amino} propionic acid (3d)
.
